"Opinion: Site C comes with too many costs, too few benefits, and should not proceed" https://t.co/wgGnc6Osbq #news #feedly
— Satya Metaclorien (@metaclorien) November 23, 2016
from Twitter https://twitter.com/metaclorien
November 22, 2016 at 07:10PM
via IFTTT